Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.

Heng D, Lee SH, Ng WK, Chan HK, Kwek JW, Tan RB.

Int J Pharm. 2013 Aug 16;452(1-2):194-200. doi: 10.1016/j.ijpharm.2013.05.006. Epub 2013 May 13.

PMID:
23680726
2.

Pulmonary drug delivery by powder aerosols.

Yang MY, Chan JG, Chan HK.

J Control Release. 2014 Nov 10;193:228-40. doi: 10.1016/j.jconrel.2014.04.055. Epub 2014 May 9. Review.

PMID:
24818765
3.

Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers.

Zhou QT, Qu L, Gengenbach T, Larson I, Stewart PJ, Morton DA.

AAPS PharmSciTech. 2013 Mar;14(1):38-44. doi: 10.1208/s12249-012-9895-z. Epub 2012 Nov 30.

4.

The development of a novel dry powder inhaler.

Zhang X, Ma Y, Zhang L, Zhu J, Jin F.

Int J Pharm. 2012 Jul 15;431(1-2):45-52. doi: 10.1016/j.ijpharm.2012.04.019. Epub 2012 Apr 20.

PMID:
22543053
5.

Device factors affecting pulmonary delivery of dry powders.

Smutney CC, Grant M, Kinsey PS.

Ther Deliv. 2013 Aug;4(8):939-49. doi: 10.4155/tde.13.77.

PMID:
23919473
6.

Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).

Zhou QT, Tong Z, Tang P, Citterio M, Yang R, Chan HK.

AAPS J. 2013 Apr;15(2):511-22. doi: 10.1208/s12248-013-9458-6. Epub 2013 Feb 1.

7.

Inhaled dry powder formulations for treating tuberculosis.

Das S, Tucker I, Stewart P.

Curr Drug Deliv. 2015;12(1):26-39. Review.

PMID:
25030114
8.

Dry powder inhalers in COPD, lung inflammation and pulmonary infections.

Muralidharan P, Hayes D Jr, Mansour HM.

Expert Opin Drug Deliv. 2015 Jun;12(6):947-62. doi: 10.1517/17425247.2015.977783. Epub 2014 Nov 12. Review.

PMID:
25388926
9.

Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.

Farkas DR, Hindle M, Longest PW.

Ann Biomed Eng. 2015 Nov;43(11):2804-15. doi: 10.1007/s10439-015-1335-2. Epub 2015 May 19.

10.

Investigation of dry powder aerosolization mechanisms in different channel designs.

Chen L, Heng RL, Delele MA, Cai J, Du DZ, Opara UL.

Int J Pharm. 2013 Nov 30;457(1):143-9. doi: 10.1016/j.ijpharm.2013.09.012. Epub 2013 Sep 18.

PMID:
24055441
11.

Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.

Behara SR, Farkas DR, Hindle M, Longest PW.

Pharm Res. 2014 Feb;31(2):360-72. doi: 10.1007/s11095-013-1165-6. Epub 2013 Aug 16.

12.

An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.

Holmes MS, Seheult JN, O'Connell P, D'Arcy S, Ehrhardt C, Healy AM, Costello RW, Reilly RB.

J Aerosol Med Pulm Drug Deliv. 2015 Aug;28(4):247-53. doi: 10.1089/jamp.2014.1169. Epub 2014 Nov 13.

PMID:
25393346
13.

Dry powder inhalers for optimal drug delivery.

Newman SP.

Expert Opin Biol Ther. 2004 Jan;4(1):23-33. Review.

PMID:
14680466
14.

Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.

Tong Z, Yu A, Chan HK, Yang R.

Curr Pharm Des. 2015;21(27):3966-73. Review.

PMID:
26290194
15.

Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.

Le VN, Robins E, Flament MP.

Eur J Pharm Biopharm. 2010 Nov;76(3):464-9. doi: 10.1016/j.ejpb.2010.09.003. Epub 2010 Sep 18.

PMID:
20854906
16.

Applications of capsule dosing techniques for use in dry powder inhalers.

Edwards D.

Ther Deliv. 2010 Jul;1(1):195-201. Review.

PMID:
22816126
17.

Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.

Young PM, Crapper J, Philips G, Sharma K, Chan HK, Traini D.

J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):138-47. doi: 10.1089/jamp.2013.1080. Epub 2013 Sep 4.

PMID:
24004178
18.

Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.

Shur J, Lee S, Adams W, Lionberger R, Tibbatts J, Price R.

AAPS J. 2012 Dec;14(4):667-76. doi: 10.1208/s12248-012-9379-9. Epub 2012 Jun 22.

19.

Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®).

Jiang L, Tang Y, Zhang H, Lu X, Chen X, Zhu J.

J Aerosol Med Pulm Drug Deliv. 2012 Oct;25(5):265-79. doi: 10.1089/jamp.2011.0908. Epub 2012 Jan 26.

PMID:
22280548
20.

An insight into powder entrainment and drug delivery mechanisms from a modified Rotahaler®.

Sim S, Margo K, Parks J, Howell R, Hebbink GA, Orlando L, Larson I, Leslie P, Ho L, Morton DA.

Int J Pharm. 2014 Dec 30;477(1-2):351-60. doi: 10.1016/j.ijpharm.2014.08.038. Epub 2014 Sep 6.

PMID:
25196720

Supplemental Content

Support Center